Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions

Marburg (MARV) and Ebola (EBOV) viruses are zoonotic pathogens that cause severe hemorrhagic fever in humans. The natural reservoir of MARV is the Egyptian rousette bat ( ); that of EBOV is unknown but believed to be another bat species. The Egyptian rousette develops subclinical productive infectio...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of virology Vol. 91; no. 8
Main Authors:	Kuzmin, Ivan V, Schwarz, Toni M, Ilinykh, Philipp A, Jordan, Ingo, Ksiazek, Thomas G, Sachidanandam, Ravi, Basler, Christopher F, Bukreyev, Alexander
Format:	Journal Article
Language:	English
Published:	United States 15.04.2017
Subjects:	Animals Cell Line Chiroptera Ebolavirus - immunology Ebolavirus - physiology Humans Immune Tolerance Immunity, Innate Interferons - analysis Marburgvirus - immunology Marburgvirus - physiology Protein Domains Viral Proteins - immunology Virus Replication Ebola virus interferons natural host Marburg virus bat immune evasion accidental host interferon-inhibiting domain
ISSN:	1098-5514, 1098-5514
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Marburg (MARV) and Ebola (EBOV) viruses are zoonotic pathogens that cause severe hemorrhagic fever in humans. The natural reservoir of MARV is the Egyptian rousette bat ( ); that of EBOV is unknown but believed to be another bat species. The Egyptian rousette develops subclinical productive infection with MARV but is refractory to EBOV. Interaction of filoviruses with hosts is greatly affected by the viral interferon (IFN)-inhibiting domains (IID). Our study was aimed at characterization of innate immune responses to filoviruses and the role of filovirus IID in bat and human cells. The study demonstrated that EBOV and MARV replicate to similar levels in all tested cell lines, indicating that permissiveness for EBOV at cell and organism levels do not necessarily correlate. Filoviruses, particularly MARV, induced a potent innate immune response in rousette cells, which was generally stronger than that in human cells. Both EBOV VP35 and VP24 IID were found to suppress the innate immune response in rousette cells, but only VP35 IID appeared to promote virus replication. Along with IFN-α and IFN-β, IFN-γ was demonstrated to control filovirus infection in bat cells but not in human cells, suggesting host species specificity of the antiviral effect. The antiviral effects of bat IFNs appeared not to correlate with induction of IFN-stimulated genes 54 and 56, which were detected in human cells ectopically expressing bat IFN-α and IFN-β. As bat IFN-γ induced the type I IFN pathway, its antiviral effect is likely to be partially induced via cross talk. Bats serve as reservoirs for multiple emerging viruses, including filoviruses, henipaviruses, lyssaviruses, and zoonotic coronaviruses. Although there is no evidence for symptomatic disease caused by either Marburg or Ebola viruses in bats, spillover of these viruses into human populations causes deadly outbreaks. The reason for the lack of symptomatic disease in bats infected with filoviruses remains unknown. The outcome of a virus-host interaction depends on the ability of the host immune system to suppress viral replication and the ability of a virus to counteract the host defenses. Our study is a comparative analysis of the host innate immune response to either MARV or EBOV infection in bat and human cells and the role of viral interferon-inhibiting domains in the host innate immune responses. The data are useful for understanding the interactions of filoviruses with natural and accidental hosts and for identification of factors that influence filovirus evolution.
AbstractList	Marburg (MARV) and Ebola (EBOV) viruses are zoonotic pathogens that cause severe hemorrhagic fever in humans. The natural reservoir of MARV is the Egyptian rousette bat (Rousettus aegyptiacus); that of EBOV is unknown but believed to be another bat species. The Egyptian rousette develops subclinical productive infection with MARV but is refractory to EBOV. Interaction of filoviruses with hosts is greatly affected by the viral interferon (IFN)-inhibiting domains (IID). Our study was aimed at characterization of innate immune responses to filoviruses and the role of filovirus IID in bat and human cells. The study demonstrated that EBOV and MARV replicate to similar levels in all tested cell lines, indicating that permissiveness for EBOV at cell and organism levels do not necessarily correlate. Filoviruses, particularly MARV, induced a potent innate immune response in rousette cells, which was generally stronger than that in human cells. Both EBOV VP35 and VP24 IID were found to suppress the innate immune response in rousette cells, but only VP35 IID appeared to promote virus replication. Along with IFN-α and IFN-β, IFN-γ was demonstrated to control filovirus infection in bat cells but not in human cells, suggesting host species specificity of the antiviral effect. The antiviral effects of bat IFNs appeared not to correlate with induction of IFN-stimulated genes 54 and 56, which were detected in human cells ectopically expressing bat IFN-α and IFN-β. As bat IFN-γ induced the type I IFN pathway, its antiviral effect is likely to be partially induced via cross talk.IMPORTANCE Bats serve as reservoirs for multiple emerging viruses, including filoviruses, henipaviruses, lyssaviruses, and zoonotic coronaviruses. Although there is no evidence for symptomatic disease caused by either Marburg or Ebola viruses in bats, spillover of these viruses into human populations causes deadly outbreaks. The reason for the lack of symptomatic disease in bats infected with filoviruses remains unknown. The outcome of a virus-host interaction depends on the ability of the host immune system to suppress viral replication and the ability of a virus to counteract the host defenses. Our study is a comparative analysis of the host innate immune response to either MARV or EBOV infection in bat and human cells and the role of viral interferon-inhibiting domains in the host innate immune responses. The data are useful for understanding the interactions of filoviruses with natural and accidental hosts and for identification of factors that influence filovirus evolution.Marburg (MARV) and Ebola (EBOV) viruses are zoonotic pathogens that cause severe hemorrhagic fever in humans. The natural reservoir of MARV is the Egyptian rousette bat (Rousettus aegyptiacus); that of EBOV is unknown but believed to be another bat species. The Egyptian rousette develops subclinical productive infection with MARV but is refractory to EBOV. Interaction of filoviruses with hosts is greatly affected by the viral interferon (IFN)-inhibiting domains (IID). Our study was aimed at characterization of innate immune responses to filoviruses and the role of filovirus IID in bat and human cells. The study demonstrated that EBOV and MARV replicate to similar levels in all tested cell lines, indicating that permissiveness for EBOV at cell and organism levels do not necessarily correlate. Filoviruses, particularly MARV, induced a potent innate immune response in rousette cells, which was generally stronger than that in human cells. Both EBOV VP35 and VP24 IID were found to suppress the innate immune response in rousette cells, but only VP35 IID appeared to promote virus replication. Along with IFN-α and IFN-β, IFN-γ was demonstrated to control filovirus infection in bat cells but not in human cells, suggesting host species specificity of the antiviral effect. The antiviral effects of bat IFNs appeared not to correlate with induction of IFN-stimulated genes 54 and 56, which were detected in human cells ectopically expressing bat IFN-α and IFN-β. As bat IFN-γ induced the type I IFN pathway, its antiviral effect is likely to be partially induced via cross talk.IMPORTANCE Bats serve as reservoirs for multiple emerging viruses, including filoviruses, henipaviruses, lyssaviruses, and zoonotic coronaviruses. Although there is no evidence for symptomatic disease caused by either Marburg or Ebola viruses in bats, spillover of these viruses into human populations causes deadly outbreaks. The reason for the lack of symptomatic disease in bats infected with filoviruses remains unknown. The outcome of a virus-host interaction depends on the ability of the host immune system to suppress viral replication and the ability of a virus to counteract the host defenses. Our study is a comparative analysis of the host innate immune response to either MARV or EBOV infection in bat and human cells and the role of viral interferon-inhibiting domains in the host innate immune responses. The data are useful for understanding the interactions of filoviruses with natural and accidental hosts and for identification of factors that influence filovirus evolution. Marburg (MARV) and Ebola (EBOV) viruses are zoonotic pathogens that cause severe hemorrhagic fever in humans. The natural reservoir of MARV is the Egyptian rousette bat ( ); that of EBOV is unknown but believed to be another bat species. The Egyptian rousette develops subclinical productive infection with MARV but is refractory to EBOV. Interaction of filoviruses with hosts is greatly affected by the viral interferon (IFN)-inhibiting domains (IID). Our study was aimed at characterization of innate immune responses to filoviruses and the role of filovirus IID in bat and human cells. The study demonstrated that EBOV and MARV replicate to similar levels in all tested cell lines, indicating that permissiveness for EBOV at cell and organism levels do not necessarily correlate. Filoviruses, particularly MARV, induced a potent innate immune response in rousette cells, which was generally stronger than that in human cells. Both EBOV VP35 and VP24 IID were found to suppress the innate immune response in rousette cells, but only VP35 IID appeared to promote virus replication. Along with IFN-α and IFN-β, IFN-γ was demonstrated to control filovirus infection in bat cells but not in human cells, suggesting host species specificity of the antiviral effect. The antiviral effects of bat IFNs appeared not to correlate with induction of IFN-stimulated genes 54 and 56, which were detected in human cells ectopically expressing bat IFN-α and IFN-β. As bat IFN-γ induced the type I IFN pathway, its antiviral effect is likely to be partially induced via cross talk. Bats serve as reservoirs for multiple emerging viruses, including filoviruses, henipaviruses, lyssaviruses, and zoonotic coronaviruses. Although there is no evidence for symptomatic disease caused by either Marburg or Ebola viruses in bats, spillover of these viruses into human populations causes deadly outbreaks. The reason for the lack of symptomatic disease in bats infected with filoviruses remains unknown. The outcome of a virus-host interaction depends on the ability of the host immune system to suppress viral replication and the ability of a virus to counteract the host defenses. Our study is a comparative analysis of the host innate immune response to either MARV or EBOV infection in bat and human cells and the role of viral interferon-inhibiting domains in the host innate immune responses. The data are useful for understanding the interactions of filoviruses with natural and accidental hosts and for identification of factors that influence filovirus evolution.
Author	Schwarz, Toni M Kuzmin, Ivan V Sachidanandam, Ravi Jordan, Ingo Basler, Christopher F Bukreyev, Alexander Ilinykh, Philipp A Ksiazek, Thomas G
Author_xml	– sequence: 1 givenname: Ivan V surname: Kuzmin fullname: Kuzmin, Ivan V organization: Galveston National Laboratory, The University of Texas Medical Branch, Galveston, Texas, USA – sequence: 2 givenname: Toni M surname: Schwarz fullname: Schwarz, Toni M organization: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA – sequence: 3 givenname: Philipp A surname: Ilinykh fullname: Ilinykh, Philipp A organization: Galveston National Laboratory, The University of Texas Medical Branch, Galveston, Texas, USA – sequence: 4 givenname: Ingo surname: Jordan fullname: Jordan, Ingo organization: ProBioGen AG, Berlin, Germany – sequence: 5 givenname: Thomas G surname: Ksiazek fullname: Ksiazek, Thomas G organization: Department Microbiology & Immunology, The University of Texas Medical Branch, Galveston, Texas, USA – sequence: 6 givenname: Ravi surname: Sachidanandam fullname: Sachidanandam, Ravi organization: Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA – sequence: 7 givenname: Christopher F surname: Basler fullname: Basler, Christopher F organization: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA – sequence: 8 givenname: Alexander surname: Bukreyev fullname: Bukreyev, Alexander email: alexander.bukreyev@utmb.edu organization: Department Microbiology & Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28122983$$D View this record in MEDLINE/PubMed
BookMark	eNpNkE1LxDAYhIOsuB968yw5eumapGmbetPqamVBEPUm5W2SQqRJ1iYV_PdWXMHTzOGZYZglmjnvNEKnlKwpZeLi4bVeE8YLmtD8AC0oKUWSZZTP_vk5WobwTgjlPOdHaM4EZawU6QK91c5B1Li2dnQaP-mw8y7ogH2HryFicArfjxYcrnTfBxw93pjef5phnKhLXHlrvYPeRDOFfugbE6JxMpqp5xgddtAHfbLXFXrZ3D5X98n28a6urraJ5CKNSa6ESttSMlq0hLKsIx2ITBQEWp53eZEWCoDkHU1LBZIyKQWIrtVcMVUAEWyFzn97d4P_GHWIjTVBToPBaT-GhoqcMZFmrJzQsz06tlarZjcYC8NX83cJ-wbXyWSy
CitedBy_id	crossref_primary_10_1093_molbev_msaf017 crossref_primary_10_1128_JVI_01821_18 crossref_primary_10_1007_s00203_025_04277_4 crossref_primary_10_3390_v13112186 crossref_primary_10_1016_j_antiviral_2025_106211 crossref_primary_10_1128_JVI_00250_20 crossref_primary_10_7554_eLife_48401 crossref_primary_10_1038_s41392_022_01247_w crossref_primary_10_1093_infdis_jiy473 crossref_primary_10_3390_d15040530 crossref_primary_10_3389_fimmu_2018_02112 crossref_primary_10_3389_fimmu_2019_02414 crossref_primary_10_1086_725081 crossref_primary_10_1126_science_adl2016 crossref_primary_10_1002_jmv_29772 crossref_primary_10_12688_f1000research_17573_1 crossref_primary_10_1128_mSphere_00245_17 crossref_primary_10_3390_vaccines5030030 crossref_primary_10_3390_pathogens11121400 crossref_primary_10_1007_s11262_021_01865_6 crossref_primary_10_3390_v10110607 crossref_primary_10_1007_s13364_018_0375_z crossref_primary_10_1038_s44298_024_00022_8 crossref_primary_10_3389_fmicb_2023_1151524 crossref_primary_10_3390_vaccines7010022 crossref_primary_10_1371_journal_ppat_1012471 crossref_primary_10_1093_biosci_biaf050 crossref_primary_10_3389_fimmu_2020_00435 crossref_primary_10_3390_v15020350 crossref_primary_10_1186_s12865_023_00542_7 crossref_primary_10_1371_journal_pbio_3003098 crossref_primary_10_1177_17534259221093120 crossref_primary_10_3390_v13081509 crossref_primary_10_3390_v14050936 crossref_primary_10_1038_s41579_020_0394_z crossref_primary_10_1146_annurev_virology_092818_015613 crossref_primary_10_1016_j_coviro_2024_101436
ContentType	Journal Article
Copyright	Copyright © 2017 American Society for Microbiology.
Copyright_xml	– notice: Copyright © 2017 American Society for Microbiology.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1128/JVI.02471-16
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Biology
EISSN	1098-5514
ExternalDocumentID	28122983
Genre	Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: NIAID NIH HHS grantid: T32 AI007647
GroupedDBID	--- -~X 0R~ 18M 29L 2WC 39C 4.4 53G 5GY 5RE 5VS 85S AAFWJ AAGFI ABPPZ ACGFO ACNCT ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 N9A NPM O9- OK1 P2P RHI RNS RPM RSF TR2 UPT W2D W8F WH7 WOQ YQT ~02 ~KM 7X8
ID	FETCH-LOGICAL-c483t-6d8d3b9c217b0125f0fa85870ab46f6737daa06f139dac12cc8a8fbe4d2d7a082
IEDL.DBID	7X8
ISICitedReferencesCount	47
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000399472200039&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1098-5514
IngestDate	Thu Sep 04 19:59:44 EDT 2025 Mon Jul 21 06:05:15 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	8
Keywords	Ebola virus interferons natural host Marburg virus bat immune evasion accidental host interferon-inhibiting domain
Language	English
License	Copyright © 2017 American Society for Microbiology.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c483t-6d8d3b9c217b0125f0fa85870ab46f6737daa06f139dac12cc8a8fbe4d2d7a082
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://jvi.asm.org/content/jvi/91/8/e02471-16.full.pdf
PMID	28122983
PQID	1862283529
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1862283529 pubmed_primary_28122983
PublicationCentury	2000
PublicationDate	2017-04-15
PublicationDateYYYYMMDD	2017-04-15
PublicationDate_xml	– month: 04 year: 2017 text: 2017-04-15 day: 15
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of virology
PublicationTitleAlternate	J Virol
PublicationYear	2017
References	23616668 - J Virol. 2013 Jul;87(13):7471-85 24074586 - Virology. 2013 Nov;446(1-2):230-7 18369468 - PLoS Pathog. 2008 Mar 14;4(3):e1000017 26255028 - Virology. 2015 Nov;485:145-52 20071589 - J Virol. 2010 Mar;84(6):3004-15 2108862 - EMBO J. 1990 Apr;9(4):1105-11 8969248 - Emerg Infect Dis. 1996 Oct-Dec;2(4):321-5 25375951 - J Wildl Dis. 2015 Jan;51(1):113-24 26242723 - Nat Commun. 2015 Aug 05;6:8000 26805873 - Viruses. 2016 Jan 22;8(2):null 25320312 - J Virol. 2015 Jan;89(1):312-22 25531184 - Virology. 2015 Feb;476:85-91 23029039 - PLoS One. 2012;7(9):e45479 11331912 - Nat Rev Mol Cell Biol. 2001 May;2(5):378-86 17712412 - PLoS One. 2007 Aug 22;2(8):e764 20628805 - Biochem Genet. 2010 Oct;48(9-10):840-6 20689015 - Science. 2010 Aug 6;329(5992):676-9 12469119 - Nat Immunol. 2003 Jan;4(1):63-8 9988155 - J Infect Dis. 1999 Feb;179 Suppl 1:S1-7 11967234 - FASEB J. 2002 Jun;16(8):869-71 26903655 - Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2696-701 23302292 - Zoonoses Public Health. 2013 Feb;60(1):104-16 3926890 - J Immunol. 1985 Sep;135(3):1857-63 25660265 - J Clin Virol. 2015 Mar;64:111-9 15661137 - Virology. 2005 Feb 5;332(1):20-7 23258410 - Science. 2013 Jan 25;339(6118):456-60 11972351 - Nucleic Acids Res. 2002 May 1;30(9):e36 16319873 - Nature. 2005 Dec 1;438(7068):575-6 15864272 - Nat Rev Immunol. 2005 May;5(5):375-86 21084112 - Lancet. 2011 Mar 5;377(9768):849-62 14633608 - Am J Pathol. 2003 Dec;163(6):2347-70 19540275 - Virus Res. 2009 Oct;145(1):54-62 25100081 - PLoS One. 2014 Aug 06;9(8):e103875 20645874 - J Interferon Cytokine Res. 2010 Aug;30(8):573-8 21278349 - J Immunol. 2011 Mar 1;186(5):3138-47 25494448 - Viruses. 2014 Dec;6(12):4880-901 17498518 - J Comp Pathol. 2007 May;136(4):266-72 23378666 - Proc Biol Sci. 2013 Feb 01;280(1756):20122753 24391501 - PLoS Pathog. 2014 Jan;10 (1):e1003845 24747773 - Viruses. 2014 Apr 17;6(4):1759-88 15546383 - Immunol Rev. 2004 Dec;202:8-32 25838270 - J Infect Dis. 2015 Oct 1;212 Suppl 2:S109-18 11832212 - Cell. 2002 Jan 25;108(2):221-32 10430035 - Biol Chem. 1999 Jun;380(6):699-703 16775337 - J Virol. 2006 Jul;80(13):6497-516 16775331 - J Virol. 2006 Jul;80(13):6430-40 26120867 - Viruses. 2015 Jun 25;7(7):3420-42 20663124 - BMC Genomics. 2010 Jul 21;11:444 21840693 - Curr Opin Immunol. 2011 Oct;23(5):583-90 27713552 - Sci Rep. 2016 Oct 07;6:34589 20084112 - PLoS Pathog. 2010 Jan 15;6(1):e1000721 25972536 - J Virol. 2015 Aug;89(15):7567-83 12502864 - J Virol. 2003 Jan;77(2):1501-11 19889762 - J Virol. 2010 Jan;84(2):1169-75 27930745 - PLoS Pathog. 2016 Dec 8;12 (12 ):e1006031 21987760 - J Infect Dis. 2011 Nov;204 Suppl 3:S840-9 19649327 - PLoS Pathog. 2009 Jul;5(7):e1000536 26439085 - Nat Rev Microbiol. 2015 Nov;13(11):663-76 26402433 - Emerg Infect Dis. 2015 Oct;21(10):1840-3 24738640 - N Engl J Med. 2014 Oct 9;371(15):1418-25 26643810 - BMC Genomics. 2015 Dec 07;16:1033 24742338 - Expert Rev Clin Immunol. 2014 Jun;10(6):781-90 12483210 - Nat Immunol. 2003 Jan;4(1):69-77 26562011 - PLoS Pathog. 2015 Nov 12;11(11):e1005263
References_xml	– reference: 11331912 - Nat Rev Mol Cell Biol. 2001 May;2(5):378-86 – reference: 19889762 - J Virol. 2010 Jan;84(2):1169-75 – reference: 9988155 - J Infect Dis. 1999 Feb;179 Suppl 1:S1-7 – reference: 26903655 - Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2696-701 – reference: 15864272 - Nat Rev Immunol. 2005 May;5(5):375-86 – reference: 26242723 - Nat Commun. 2015 Aug 05;6:8000 – reference: 16319873 - Nature. 2005 Dec 1;438(7068):575-6 – reference: 17712412 - PLoS One. 2007 Aug 22;2(8):e764 – reference: 20628805 - Biochem Genet. 2010 Oct;48(9-10):840-6 – reference: 21084112 - Lancet. 2011 Mar 5;377(9768):849-62 – reference: 23258410 - Science. 2013 Jan 25;339(6118):456-60 – reference: 16775337 - J Virol. 2006 Jul;80(13):6497-516 – reference: 24747773 - Viruses. 2014 Apr 17;6(4):1759-88 – reference: 19540275 - Virus Res. 2009 Oct;145(1):54-62 – reference: 23378666 - Proc Biol Sci. 2013 Feb 01;280(1756):20122753 – reference: 11967234 - FASEB J. 2002 Jun;16(8):869-71 – reference: 20645874 - J Interferon Cytokine Res. 2010 Aug;30(8):573-8 – reference: 14633608 - Am J Pathol. 2003 Dec;163(6):2347-70 – reference: 25531184 - Virology. 2015 Feb;476:85-91 – reference: 24738640 - N Engl J Med. 2014 Oct 9;371(15):1418-25 – reference: 23616668 - J Virol. 2013 Jul;87(13):7471-85 – reference: 20689015 - Science. 2010 Aug 6;329(5992):676-9 – reference: 20084112 - PLoS Pathog. 2010 Jan 15;6(1):e1000721 – reference: 8969248 - Emerg Infect Dis. 1996 Oct-Dec;2(4):321-5 – reference: 3926890 - J Immunol. 1985 Sep;135(3):1857-63 – reference: 15546383 - Immunol Rev. 2004 Dec;202:8-32 – reference: 25375951 - J Wildl Dis. 2015 Jan;51(1):113-24 – reference: 10430035 - Biol Chem. 1999 Jun;380(6):699-703 – reference: 12483210 - Nat Immunol. 2003 Jan;4(1):69-77 – reference: 23029039 - PLoS One. 2012;7(9):e45479 – reference: 15661137 - Virology. 2005 Feb 5;332(1):20-7 – reference: 11832212 - Cell. 2002 Jan 25;108(2):221-32 – reference: 26439085 - Nat Rev Microbiol. 2015 Nov;13(11):663-76 – reference: 23302292 - Zoonoses Public Health. 2013 Feb;60(1):104-16 – reference: 24074586 - Virology. 2013 Nov;446(1-2):230-7 – reference: 26120867 - Viruses. 2015 Jun 25;7(7):3420-42 – reference: 2108862 - EMBO J. 1990 Apr;9(4):1105-11 – reference: 25660265 - J Clin Virol. 2015 Mar;64:111-9 – reference: 25100081 - PLoS One. 2014 Aug 06;9(8):e103875 – reference: 25972536 - J Virol. 2015 Aug;89(15):7567-83 – reference: 11972351 - Nucleic Acids Res. 2002 May 1;30(9):e36 – reference: 26805873 - Viruses. 2016 Jan 22;8(2):null – reference: 26562011 - PLoS Pathog. 2015 Nov 12;11(11):e1005263 – reference: 25320312 - J Virol. 2015 Jan;89(1):312-22 – reference: 25838270 - J Infect Dis. 2015 Oct 1;212 Suppl 2:S109-18 – reference: 12502864 - J Virol. 2003 Jan;77(2):1501-11 – reference: 24391501 - PLoS Pathog. 2014 Jan;10 (1):e1003845 – reference: 20663124 - BMC Genomics. 2010 Jul 21;11:444 – reference: 24742338 - Expert Rev Clin Immunol. 2014 Jun;10(6):781-90 – reference: 21278349 - J Immunol. 2011 Mar 1;186(5):3138-47 – reference: 25494448 - Viruses. 2014 Dec;6(12):4880-901 – reference: 16775331 - J Virol. 2006 Jul;80(13):6430-40 – reference: 27713552 - Sci Rep. 2016 Oct 07;6:34589 – reference: 18369468 - PLoS Pathog. 2008 Mar 14;4(3):e1000017 – reference: 26643810 - BMC Genomics. 2015 Dec 07;16:1033 – reference: 12469119 - Nat Immunol. 2003 Jan;4(1):63-8 – reference: 19649327 - PLoS Pathog. 2009 Jul;5(7):e1000536 – reference: 21840693 - Curr Opin Immunol. 2011 Oct;23(5):583-90 – reference: 26402433 - Emerg Infect Dis. 2015 Oct;21(10):1840-3 – reference: 21987760 - J Infect Dis. 2011 Nov;204 Suppl 3:S840-9 – reference: 26255028 - Virology. 2015 Nov;485:145-52 – reference: 17498518 - J Comp Pathol. 2007 May;136(4):266-72 – reference: 27930745 - PLoS Pathog. 2016 Dec 8;12 (12 ):e1006031 – reference: 20071589 - J Virol. 2010 Mar;84(6):3004-15
SSID	ssj0014464
Score	2.4642708
Snippet	Marburg (MARV) and Ebola (EBOV) viruses are zoonotic pathogens that cause severe hemorrhagic fever in humans. The natural reservoir of MARV is the Egyptian...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
SubjectTerms	Animals Cell Line Chiroptera Ebolavirus - immunology Ebolavirus - physiology Humans Immune Tolerance Immunity, Innate Interferons - analysis Marburgvirus - immunology Marburgvirus - physiology Protein Domains Viral Proteins - immunology Virus Replication
Title	Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions
URI	https://www.ncbi.nlm.nih.gov/pubmed/28122983 https://www.proquest.com/docview/1862283529
Volume	91
WOSCitedRecordID	wos000399472200039&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UKnhxX-rGCF5jk0nSzHgRt2JFSxGVXiTMCoUyqU1a8N_7JknpSRC85DSB8PKW7y3zPoQuYoANimnjBcRXXiRjMCnFQy9moEGS-pGotus_J70eHQxYvy645fVY5dwnlo5aZdLVyFsBQG-3G4yw6_GX51ijXHe1ptBYRo0QoIwb6UoGiy4CpDplV9ntzHTIYD74Tmjr6aN7CeEpcSzJv4PLMsh0Nv_7eVtoo4aX-KbSh220pO0OWqsIJ7930WfXWgCXuOtuhWj8Wg3I6hxnBt_yAnOrcFnWx3d6NMpxkeHOcJTNhpMpnLrC7jpJBd0hwS5P3zsfYcvLEfkeeu88vN09ejXBgicjGhZeW1EVCiYhLREQqGLjG05jsGAuorZxDDaKc79tQLSKy4BISTk1QkeKqIQDeNhHKzaz-hBhKTj8V66ZIiKiImJcQiKoFTNSy4CTJjqfyy0FBXZdCW51Ns3TheSa6KASfjquNm2kBOAHYTQ8-sPbx2iduJDr9jDGJ6hhwHz1KVqVs2KYT85KzYBnr__yA8m9xBw
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Innate+Immune+Responses+of+Bat+and+Human+Cells+to+Filoviruses%3A+Commonalities+and+Distinctions&rft.jtitle=Journal+of+virology&rft.au=Kuzmin%2C+Ivan+V&rft.au=Schwarz%2C+Toni+M&rft.au=Ilinykh%2C+Philipp+A&rft.au=Jordan%2C+Ingo&rft.date=2017-04-15&rft.eissn=1098-5514&rft.volume=91&rft.issue=8&rft_id=info:doi/10.1128%2FJVI.02471-16&rft_id=info%3Apmid%2F28122983&rft_id=info%3Apmid%2F28122983&rft.externalDocID=28122983
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-5514&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-5514&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-5514&client=summon